Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine

Journal of Clinical Psychiatry

Volumn 70, Issue 1, 2009, Pages 95-100

  Yasui Furukori, Norio ^a   Sato, Yasushi ^a   Furukori, Hanako ^a   Saito, Manabu ^a   Nakagami, Taku ^a   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; GLUCOSE; HALOPERIDOL; INSULIN; LEVOMEPROMAZINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SORBITOL; ZIPRASIDONE; ZOTEPINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASIAN; BODY MASS; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG SUBSTITUTION; ERYTHROCYTE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; JAPAN; JAPANESE; MALE; MENTAL HOSPITAL; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SCHIZOPHRENIA; UNIVERSITY HOSPITAL;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; JAPAN; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA;

EID: 60349117937     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.07m03829     Document Type: Article

References (58)

1. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998 Jul;173:11-53
2. Joukamaa M, Heliovaara M, Knekt P, et al. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006;188:122-127
3. Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004;65(suppl 18):36-46
4. Lean M MEJ, Pajonk FG. Patients on atypical antipsychotic drugs another high-risk group for type 2 diabetes. Diabetes Care 2003;26: 1597-1605
5. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999;100:3-16
6. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156: 1686-1696
7. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000;157:975-981
8. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002 Oct;63(10): 856-865
9. Kabinoff GS, Toalson PA, Healey KM, et al. Metabolic issues with atypical antipsychotics in primary care: dispelling the myths. Prim Care Companion J Clin Psychiatry 2003 Feb;5(1):6-14
10. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-566
11. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002 Oct;63(10):920-930
12. Caro JJ, Ward A, Levinton C, et al. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002 Dec;63(12):1135-1139
13. Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003 May;64(5):598-604
14. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002 Aug;325(7358):243
15. Vieweg WVR, Sood AB, Pandurangi A, et al. Newer antipsychotic drugs and obesity in children and adolescents: how should we assess drug-associated weight gain? Acta Psychiatr Scand 2005;111:177-184
16. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-296
17. Citrome L, Jaffe A, Levine J, et al. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004;55:1006-1013
18. Koller EA, Cross JT, Doraiswamy PM, et al. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003; 23(6):735-744
19. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002;22(7):841-852
20. Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 2007;33:169-175
21. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(suppl 1):1-93
22. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormality in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337-345
23. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005;62:19-28
24. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
25. The DECODA Study Group. Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care 2003;26:1770-1780
26. Mizoue T, Yamaji T, Tabata S, et al. Dietary patterns and glucose tolerance abnormalities in Japanese men. J Nutr 2006;136:1352-1358
27. McNeely MJ, Boyko EJ. Type 2 diabetes prevalence in Asian Americans: results of a national health survey. Diabetes Care 2004;27:66-69
28. Petersen KF, Dufour S, Feng J, et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A 2006 Nov;103(48):18273-18277
29. Tripathy D, Tuomi T, Almgren P. Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care 2004;27:2204-2210
30. Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002 Jul;25(7):1135-1141
31. Bock G, Dalla MC, Campioni M, et al. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 2006 Dec;55(12):3536-3549
32. Meyer C, Pimenta W, Woerle HJ, et al. Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 2006 Aug;29(8):1909-1914
33. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006 May;29(5):1130-1139
34. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003 Jun;64(6):663-667
35. American Diabetes Association. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004;27:596-601
36. Kane JM, Barrett EJ, Casey DE, et al. Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry 2004 Nov;65(11):1447-1455
37. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
38. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005 Apr;66(4):504-514
39. Sowell M, Mukhopadhyay N, Cavazzoni P, et al. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 2003;88:5875-5880
40. Sowell MO, Mukhopadhyay N, Cavazzoni P, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 2002;87: 2918-2923
41. Ader M, Kim SP, Catalano KJ, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005;54:862-871
42. Dwyer DS, Lu XH, Bradley RJ, et al. Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Brain Res 2003;971:31-39
43. Vestri HS, Maianu L, Moellering DR, et al. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 2007 Apr;32(4):765-772
44. Johnson DE, Yamazaki H, Ward KM, et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perfused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 2005;54:1552-1558
45. Hamanaka S, Kamijo Y. New-onset diabetic ketoacidosis induced by the addition of perospirone hydrochloride in a patient treated with risperidone. Intern Med 2007;46(4):199-200
46. Sato Y, Yasui-Furukori N, Moriyama T, et al. New-onset diabetic ketoacidosis in a schizophrenic patient with multiple autoimmune disease during treatment with risperidone. Prog Neuropsychopharmacol Biol Psychiatry 2008 Feb;32(2):577-578
47. Fujimoto WY, Bergstrom RW, Boyko EJ, et al. Susceptibility to development of central adiposity among populations. Obes Res 1995 Sep;3(suppl 2):179S-186S
48. Park YW, Allison DB, Heymsfield SB, et al. Larger amounts of visceral adipose tissue in Asian Americans. Obes Res 2001 Jul;9(7):381-387
49. Shin CS, Lee HK, Koh CS, et al. Risk factors for the development of NIDDM in Yonchon County, Korea. Diabetes Care 1997 Dec;20(12): 1842-1846
50. Henderson DC, Cagliero E, Copeland PM, et al. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry 2007 Apr;68(4):533-541
51. Lieberman JA III. Metabolic changes associated with antipsychotic use. Prim Care Companion J Clin Psychiatry 2004;6(suppl 2):8-13
52. Henderson DC. Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 2005;66(suppl 6):11-20
53. De Hert MA, Winkel BV, Eyck DV, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006;83:87-93
54. Zhang ZJ, Yao ZJ, Liu W, et al. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously, untreated people with schizophrenia. Br J Psychiatry 2004;184:58-62
55. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003 Jan;26(suppl 1):S5-S20
56. Fedele D, Comi G, Coscelli C, et al. A multicenter study on the prevalence of diabetic neuropathy in Italy: Italian Diabetic Neuropathy Committee. Diabetes Care 1997;20:836-843
57. Oates PJ. Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol 2002;50:325-392
58. Gabbay KH, O'Sullivan JB. The sorbitol pathway: enzyme location and content in normal and diabetic nerve and cord. Diabetes 1968;17:239-243